ArticleBreast cancer research and treatment2026
Factors influencing discussion duration in breast cancer multidisciplinary team meetings: insights for streamlining care.
Article in Breast cancer research and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeMultidisciplinary team meetings (MDTMs) in breast cancer care improve outcomes but are time-consuming and costly. This study investigates using data from the Dutch national cancer registry (NCR) and hospital electronic medical records (EMR) to efficiently calculate MDTM discussion durations, while complying with privacy laws.
methodsThis retrospective study analyzed breast cancer MDTM discussion durations using NCR and EMR data from 2014 to 2018. Discussion times were estimated from EMR timestamps, excluding outliers, and analyzed statistically. Ethical approval was obtained, including only non-opt-out patients.
resultsThe final dataset included 1,048 tumors, 996 patients, and 1,487 MDTM discussion times after exclusions for missing data, duplicates, and outliers. Discussion durations varied significantly, with pre-operative and no-surgery discussions being longer than post-operative ones (p = 0.000), and factors such as MRI availability, tumor differentiation, malignancy, menopausal status, and cancer stage influencing duration in pre-operative cases. In post-operative discussions, molecular subtype, cancer stage, and tumor size were significant, while age, tumor differentiation, and menopausal status had no impact.
conclusionThis study evaluates discussion durations in breast cancer MDTMs using retrospective data from the NCR and EMR, demonstrating a feasible approach to assess MDTM functioning. Differences in discussion duration based on patient and tumor characteristics may help optimize MDTM efficiency. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.